TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02353767

Intervention type: PROCEDURE
Intervention: Noninvasive evaluation of liver fibrosis and steatosis
Description: Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)

Intervention type: PROCEDURE
Intervention: Noninvasive evaluation of liver fibrosis and steatosis
Description: Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
Study: NCT01707914

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese bayberry juice
Description: Consume 500 mL CBJ/d (250 mL CBJ twice daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02967250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Description: Subjects will be provided \~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over \~2 weeks to a stable dose for 4 weeks.
Study: NCT02478138

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel lymph node mapping
Description: Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green (ICG)

Intervention type: DEVICE
Group type: OTHER
Intervention: near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)
Study: NCT01723163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence Reinforcement Therapy (ART)
Description: Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Counseling and NRT
Description: Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
Study: NCT00749723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraventricular etoposide
Description: prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (\>3m to \<3y 0.7 mg; \>3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
Study: NCT01403038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 1 for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 2 for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 3 for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 4 for 84 days Other interventions may be added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 5 for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix Dose Regimen 6 for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: Elagolix plus Activella Dose Regimen 7 for 84 days
Study: NCT02582853

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture for spinal fluid

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture for spinal fluid
Study: NCT00749723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraventricular etoposide
Description: prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (\>3m to \<3y 0.7 mg; \>3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraventricular etoposide
Description: prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (\>3m to \<3y 0.7 mg; \>3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraventricular etoposide
Description: prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (\>3m to \<3y 0.7 mg; \>3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
Study: NCT02582853

Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Blood sample
Study: NCT00749723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trofosfamide, etoposide
Description: maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trofosfamide, etoposide
Description: maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
Study: NCT04174690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Force platform
Description: In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
Study: NCT04240574

Intervention type: DEVICE
Group type: OTHER
Intervention: Debritom
Description: hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
Study: NCT01709370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole, PD 0332991
Study: NCT04287907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitor Group
Description: Use of colorimetric end tidal CO2 to guide provider during provision of mask ventilation, where colour change indicates effective breaths
Study: NCT02510794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
Study: NCT01606046

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vapocoolant spray
Description: spray for 5 seconds from a distance of 30 cm just before the needle EMG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical anesthetic cream
Description: application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
Study: NCT04206618

Intervention type: DRUG
Intervention: Teriparatide
Description: 1 subcutaneous injection daily for 12 months

Intervention type: DRUG
Intervention: Denosumab
Description: 1 subcutaneous injection every 6 months for 12 months
Study: NCT03529006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sequent Please inflation
Description: PCI procedure for treatment of ISR with DEB - Sequent Please - inflation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorb BVS implantation
Description: PCI procedure for treatment of ISR with Absorb BVS implantation
Study: NCT01681394

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-rich cocoa extract
Description: 250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chocolate cream
Study: NCT01779089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg po bid for 6 months
Description: Minocycline 100 mg po bid or placebo for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00123500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical Activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Environment
Description: Environment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Control Group
Study: NCT02338089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 100 micromolar solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 100 micromolar solution
Study: NCT03792256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO (or via NG- tube)
Study: NCT06722404

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapeutic foods
Description: All children were initially fed F-75 (75 kcal/ 100mL) therapeutic milk (Phase I) and then progressed to F-100 (100 kcal/ 100mL) (Phase II) and Plumpy'nuts (F-100 in spread form with iron fortification) (Phase III) with follow-up for 48 days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Therapeutic foods plus Synbiotics
Description: the intervention group received therapeutic foods plus synbiotics containing Oligomate that was fortified in F75 at the rate of 7.5 g/L containing 4.1 g/L GOS for 1 g/100 kcal dose and at the rate of 11.5 g/L containing 6.1 g/L GOS for 1.5 g/100 kcal dose while in F100 and Plumpy'nuts it was fortified at the rate of 10 g/L containing 5.5 g/L GOS for 1 g/100 kcal dose and at the rate of 15 g/L containing 8.25 g/L GOS for 1.5 g/100 kcal dose and Resiton (Lactobacillus paracasei sbsp. paracasei) 3 billion cfu/day and 6 billion cfu/day that were mixed in different combinations.
Study: NCT03792256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally (IT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally (IT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Either prednisone or prednisolone is given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given intrathecally (IT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Either prednisone or prednisolone is given PO
Study: NCT02879825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)
Study: NCT03315572

Intervention type: OTHER
Intervention: Interviewer administered version of ease of use items
Description: The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.

Intervention type: OTHER
Intervention: Interviewer administered version of ease of use items
Description: The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.

Intervention type: OTHER
Intervention: Self-administered version of ease of use items
Description: The interview will be self-administered by subjects aged 8 to 11 years.

Intervention type: OTHER
Intervention: Self-administered version of ease of use items
Description: The interview will be self-administered by subjects aged 8 to 11 years.

Intervention type: OTHER
Intervention: Caregiver version of ease of use items
Description: Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.

Intervention type: OTHER
Intervention: Caregiver version of ease of use items
Description: Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
Study: NCT01318408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
Study: NCT01699165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal filter
Description: Active nasal filter

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo nasal filter
Description: Placebo nasal filter
Study: NCT01631994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: 1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
Study: NCT04666896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored home-based exercise therapy
Description: exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard home-based exercise therapy
Description: The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
Study: NCT03787550

Intervention type: DRUG
Intervention: The Sedatives, analgesics and antibiotics
Description: The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.

Intervention type: DRUG
Intervention: The Sedatives, analgesics and antibiotics
Description: The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
Study: NCT00714415

Intervention type: DRUG
Intervention: BeneFIX
Description: Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study: NCT04014985

Intervention type: OTHER
Group type: OTHER
Intervention: An extensive biological assessment
Description: To study the morphology of red blood cells, the markers of oxidative stress and the signaling pathway of IFGF1.
Study: NCT03271502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Description: Total intravenous anesthesia with propofol and remifentanil

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation anesthesia
Description: Inhalation anesthesia with sevoflurane and remifentanil
Study: NCT02150447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor
Description: Lansoprazole 30 mg, daily
Study: NCT01280643

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study: NCT04439591

Intervention type: OTHER
Group type: OTHER
Intervention: Computerised cognitive training
Description: A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training
Description: A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
Study: NCT02548585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously.
Study: NCT02150447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, daily
Study: NCT01156103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: America SCORES, Bay Area
Description: After-school program promoting physical activity via soccer 3 days/week
Study: NCT02548585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously.
Study: NCT01760876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary intervention
Description: The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
Study: NCT02731950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate and Bupivacaine 0.125%
Description: Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
Study: NCT03209336

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）
Description: We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
Study: NCT03829566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A medication used as chemotherapy and to suppress the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: A rabbit polyclonal antibody to lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: A corticosteroid medication used to suppress the immune system and decrease inflammation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIg
Description: Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cells
Description: Infusion of patient's own stem cells